🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis

Recruitingn/aAges 50 Years - 80 YearsAllOslo University Hospital
NCT07444047 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study investigates whether an advanced MRI technique called Quantitative Susceptibility Mapping (QSM) can improve the differentiation of white matter lesions in people aged 50-70 years with multiple sclerosis (MS). In older individuals with MS, white matter changes seen on MRI may be related to MS or to other types of white matter changes, most commonly age-related changes or chronic small vessel disease. These conditions can appear similar on conventional MRI scans, making interpretation challenging. Participants will undergo routine clinical MRI, including a short additional QSM sequence, as well as brief cognitive and physical assessments. A comparison group with cerebral small vessel disease will also be included. The goal of the study is to determine whether QSM can provide more precise lesion characterization and support more accurate clinical interpretation of MRI findings

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria Multiple Sclerosis (MS) cohort (AgeMS): * Age 50-70 years * Clinically confirmed diagnosis of multiple sclerosis * Participation in the AgeMS study at Oslo University Hospital Inclusion Criteria Cerebral Small Vessel Disease (cSVD) control cohort: * Age 50-80 years * Radiological evidence of hypertensive small vessel disease on MRI * Good clinical recovery following transient ischemic attack (TIA), minor stroke, or stroke mimic diagnosis Exclusion Criteria Multiple Sclerosis (MS) cohort: * MRI contraindications * Severe psychiatric comorbidity * Major functional disability unrelated to MS or CSVD Exclusion Criteria Cerebral Small Vessel Disease (cSVD) control cohort: * MRI contraindications * Probable or definite cerebral amyloid angiopathy according to Boston criteria 2.0 * Genetic or inflammatory vasculopathies * Persistent neurological deficits * Severe psychiatric comorbidity * Major functional disability unrelated to CSVD
💊

What it tests

  • Not listed
📍

Where

1 site
Oslo University Hospital
Oslo, Norway
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy